Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.67 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1853129 | 0.83 | POLB (0.71) | POLBFKBP1AGLAKMT2AHSD17B10 | |
| SCHEMBL3973348 | 0.80 | POLB (0.71) | POLBFKBP1AGLAKMT2AHSD17B10 | |
| SCHEMBL15139607 | 0.80 | POLB (0.71) | POLBFKBP1AGLAKMT2AHSD17B10 | |
| SCHEMBL6613032 | 0.80 | POLB (0.71) | POLBFKBP1AGLAKMT2AHSD17B10 | |
| SCHEMBL3439600 | 0.80 | POLB (0.66) | POLBFKBP1AGLAKMT2AHSD17B10 | |
| SCHEMBL10048553 | 0.76 | POLB (0.66) | POLBFKBP1AGLAKMT2AALDH1A1 | |
| SCHEMBL27830860 | 0.76 | POLB (0.66) | POLBKMT2AHSD17B10ALDH1A1L3MBTL1 | |
| SCHEMBL8724983 | 0.76 | POLB (0.70) | POLBFKBP1AGLAKMT2AHSD17B10 | |
| SCHEMBL31634184 | 0.74 | POLB (0.62) | POLBKMT2AHSD17B10ALDH1A1 | |
| SCHEMBL391396 | 0.74 | POLB (0.68) | POLBKMT2AHSD17B10ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641792-B1 | PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS | NYCOMED GMBH (DE) | 2010-08-25 | — | — | EP | claimed |
| CN-1809564-A | Pyrrolodihydroisoquinolines useful as PDE10 inhibitors | ALTANA PHARMA AG (DE) | 2006-07-26 | — | — | CN | claimed |
| US-20060148840-A1 | Pyrrolodihydroisoquinolines as pde10 inhibitors | ALTANA PHARMA AG (DE) | 2006-07-06 | — | — | US | claimed |
| EP-1641792-A1 | PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS | ALTANA Pharma AG (DE) | 2006-04-05 | — | — | EP | claimed |
| WO-2005003129-A1 | PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-01-13 | — | — | WO | claimed |
| CN-103339132-A | Novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredi | YOUAI CO LTD | 2013-10-02 | — | — | CN | disclosed |
| EP-1641792-B1 | PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS | NYCOMED GMBH (DE) | 2010-08-25 | — | — | EP | disclosed |
| EP-1641457-B1 | PYRROLO-DIHYDROISOQUINOLINE DERIVATIVES AS PDE10 INHIBITORS | NYCOMED GMBH (DE) | 2009-08-05 | — | — | EP | disclosed |
| EP-1838707-B1 | NOVEL PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS | NYCOMED GMBH (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-20080161338-A1 | Novel Pyrrolodihydroisoquinolines as Pde 10 Inhibitors | ALTANA PHARMA AG (DE) | 2008-07-03 | — | — | US | disclosed |
| US-20070105840-A1 | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors | ALTANA PHARMA AG (DE) | 2007-05-10 | — | — | US | disclosed |
| CN-1809564-A | Pyrrolodihydroisoquinolines useful as PDE10 inhibitors | ALTANA PHARMA AG (DE) | 2006-07-26 | — | — | CN | disclosed |
| US-20060148840-A1 | Pyrrolodihydroisoquinolines as pde10 inhibitors | ALTANA PHARMA AG (DE) | 2006-07-06 | — | — | US | disclosed |
| EP-1641792-A1 | PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS | ALTANA Pharma AG (DE) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005003129-A1 | PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148840-A1 | Pyrrolodihydroisoquinolines as pde10 inhibitors | PDE12, PDE3A, PDE3B | POLB 1637/4885FKBP1A 712/4885GLA 2711/4885 |
| US-20080161338-A1 | Novel Pyrrolodihydroisoquinolines as Pde 10 Inhibitors | PDE12, PDE5A, PDE3A | POLB 1782/4885FKBP1A 801/4885GLA 2826/4885 |
| US-20070105840-A1 | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors | PDE12, PDE2A, PDE5A | POLB 481/4885FKBP1A 308/4885GLA 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.